Neuroglee Therapeutics, Inc.

Based in Singapore, Neuroglee Therapeutics, Inc. is dedicated to enhancing dementia and memory care through innovative digital support solutions for individuals experiencing cognitive decline and their caregivers. Founded in 2020 and headquartered in Singapore, Neuroglee Therapeutics Pte. Ltd.

specializes in cognitive health solutions, notably offering digital programs for dementia care. The company has completed 3 funding deals, with the most recent being a Series A round in September 2021, raising USD 10. 000 mn, co-led by EDBI and Openspace Ventures. The CEO and founder, Aniket Rajput, leads the company's efforts in transforming memory care services.

The total amount raised to date is USD 10. 000 mn, with a current valuation of USD 54. 004 mn. Neuroglee Health specializes in comprehensive memory and dementia care services designed to enhance the quality of life for individuals experiencing cognitive decline and support their care partners.

The core offerings include clinically proven cognitive support programs accessible through a digital platform, developed in collaboration with leading healthcare institutions like the Mayo Clinic. The services address challenges faced by patients with memory impairment and dementia, providing tailored strategies that include symptom management, cognitive exercises, and nutritional guidance. The client base consists primarily of health insurance plans, primary care groups, and neurology practices, which utilize the company's services to improve patient outcomes across various geographical markets, focusing on regions within the United States and potentially extending internationally. Neuroglee Health generates revenue through a value-based care model that fosters partnerships with healthcare organizations, offering subscription-based access to its platform for both patients and care providers.

The transactions often involve service agreements where health plans and provider groups pay for access to the platform, which includes continuous clinical support and monitoring. The company's flagship services aim to create measurable improvements in cognitive health, thereby reducing long-term care costs. Clients engage in a B2B transaction model, providing access to their patients under structured plans that align incentives for improved care delivery. Specific pricing plans and further financial arrangements are tailored to the needs of each partnership, ensuring a sustainable revenue stream.

The EBITDA for the most recent year, 2022, was USD -5,331,381. In September 2021, Neuroglee Therapeutics Pte. Ltd. raised USD 10.

000 mn in Series A funding to launch virtual neurology clinics and support its expansion to Boston. The company plans to introduce new products focused on enhancing patient care and may aim to expand into additional U. S. markets while leveraging this funding to strengthen its operational capabilities and outreach.